Prostate-specific antigen-based screening: controversy and guidelines

BMC Medicine

Gerald L Andriole¹  Eric H Kim¹ 

[1] Washington University School of Medicine, 4960 Children’s Place, St. Louis 63110, MO, USA

关键词: Guidelines;    Prostatectomy;    Watchful waiting;    Active surveillance;    Cancer screening tests;    Cancer screening;    Prostate cancer;    PSA;    Prostate-specific antigen;   

Others  :  1140479
DOI  :  10.1186/s12916-015-0296-5

 received in 2015-02-13, accepted in 2015-02-13,  发布年份 2015

【 摘 要 】

Although prostate-specific antigen (PSA) screening has improved the detection of prostate cancer, allowing for stage migration to less advanced disease, the precise mortality benefit of early detection is unclear. This is in part due to a discrepancy between the two large randomized controlled trials comparing PSA screening to usual care. The European Randomized Study of Screening for Prostate Cancer (ERSPC) found a survival benefit to screening, while the United States Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial did not. Furthermore, the benefit of immediate surgical intervention for screen-detected prostate cancer is unclear, as the results superficially differ between the two large randomized controlled trials comparing prostatectomy to observation. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) found no survival benefit for prostatectomy in PSA screened U.S. men, while the Scandinavian Prostate Cancer Group Study Number Four (SPCG-4) found a survival benefit for prostatectomy in clinically diagnosed prostate cancer. As a result of the controversy surrounding PSA screening and subsequent prostate cancer treatment, guidelines vary widely by organization.

【 授权许可】

   
2015 Kim and Andriole; licensee BioMed Central.

【 图 表 】

Figure 4.

【 参考文献 】

• [1]Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al.: Measurement of prostate-specific antigen in serum as screening test for prostate cancer. N Engl J Med 1991, 324:1156-61.
• [2]Potosky AL, Miller BA, Albertsen PC, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995, 273:548-52.
• [3]Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270:948-54.
• [4]Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al.: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995, 274:1445-9.
• [5]Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al.: Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. NIH, Bethesda, MD; 1999.
• [6]Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993, 119:914-23.
• [7]Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992, 267:2191-6.
• [8]Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274:626-31.
• [9]Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al.: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994, 330:242-8.
• [10]Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al.: Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000, 21:273S-309.
• [11]Schroder FH, Denis LJ, Roobol M: The story of the European randomized study of screening for prostate cancer. BJU Int 2003, 92:1-13.
• [12]Loeb S: Guideline of guidelines: prostate cancer screening. BJU Int 2014, 114:323-5.
• [13]Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-9.
• [14]Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:1-8.
• [15]Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al.: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-8.
• [16]Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366:981-90.
• [17]Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al.: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years follow-up. Lancet 2014, 384:6-12.
• [18]Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al.: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-32.
• [19]Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al.: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-92.
• [20]Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al.: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-13.
• [21]Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-17.
• [22]Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al.: Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011, 117:1210-9.
• [23]Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al.: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60:70-98.
• [24]Moyer VA: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157:120-34.
• [25]Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al.: Early detection of prostate cancer: AUA guideline. J Urol 2013, 190:419-26.
• [26]Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al.: Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013, 64:347-54.
• [27]Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P: Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2013, 158:761-9.
• [28]National Comprehensive Cancer Network. (2014). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): prostate cancer early detection. Version 1.2014. March 10, 2014.
• [29]Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, et al.: The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int 2014, 113:186-8.
• [30]Lane JA, Donovan JP, Davis M, Walsh E, Dedman D, Down L, et al.: Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic and baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol 2014, 15:1109-18.